Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLBSNASDAQ:GNLXNASDAQ:KYTXNASDAQ:NAUT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLBSCaladrius Biosciences$6.37$0.38▼$1.24$26.05M0.91522,308 shs466,373 shsGNLXGenelux$2.58+3.6%$2.73$1.60▼$5.89$97.36M-0.33209,007 shs56,125 shsKYTXKyverna Therapeutics$2.27-8.1%$2.12$1.78▼$16.64$98.11M2.17420,206 shs524,822 shsNAUTNautilus Biotechnology$0.73-6.6%$0.79$0.66▼$3.09$92.35M1.41117,876 shs195,236 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLBSCaladrius Biosciences0.00%0.00%0.00%0.00%0.00%GNLXGenelux+3.61%+4.03%-11.03%-46.69%-46.91%KYTXKyverna Therapeutics-8.10%-2.16%+6.57%-18.35%-82.97%NAUTNautilus Biotechnology-6.62%-11.15%-1.35%-52.46%-73.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLBSCaladrius BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGNLXGenelux1.107 of 5 stars3.62.00.00.00.60.00.0KYTXKyverna Therapeutics2.1599 of 5 stars3.53.00.00.02.61.70.0NAUTNautilus Biotechnology2.3087 of 5 stars3.02.00.00.00.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLBSCaladrius Biosciences 0.00N/AN/AN/AGNLXGenelux 3.20Buy$17.75587.98% UpsideKYTXKyverna Therapeutics 3.00Buy$18.33707.64% UpsideNAUTNautilus Biotechnology 2.00Hold$2.42230.10% UpsideCurrent Analyst Ratings BreakdownLatest CLBS, GNLX, NAUT, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.004/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/25/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.002/28/2025NAUTNautilus BiotechnologyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.50(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLBSCaladrius BiosciencesN/AN/AN/AN/A$1.54 per shareN/AGNLXGenelux$8K12,169.54N/AN/A$0.73 per share3.53KYTXKyverna Therapeutics$7.03M13.96N/AN/AN/A∞NAUTNautilus BiotechnologyN/AN/AN/AN/A$2.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLBSCaladrius Biosciences-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/AGNLXGenelux-$28.30M-$0.88N/AN/AN/AN/A-105.05%-80.16%N/AKYTXKyverna Therapeutics-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)NAUTNautilus Biotechnology-$63.67M-$0.54N/AN/AN/AN/A-28.85%-24.93%7/29/2025 (Estimated)Latest CLBS, GNLX, NAUT, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A4/29/2025Q1 2025NAUTNautilus Biotechnology-$0.14-$0.13+$0.01-$0.13N/AN/A3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/A3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLBSCaladrius BiosciencesN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLBSCaladrius BiosciencesN/A22.3322.33GNLXGeneluxN/A6.476.47KYTXKyverna TherapeuticsN/A10.5010.50NAUTNautilus BiotechnologyN/A16.6516.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLBSCaladrius Biosciences15.57%GNLXGenelux37.33%KYTXKyverna Therapeutics18.08%NAUTNautilus Biotechnology50.71%Insider OwnershipCompanyInsider OwnershipCLBSCaladrius Biosciences2.20%GNLXGenelux9.30%KYTXKyverna Therapeutics22.00%NAUTNautilus Biotechnology41.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLBSCaladrius Biosciences2760.58 million59.25 millionOptionableGNLXGenelux1037.74 million31.33 millionNot OptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionableNAUTNautilus Biotechnology130126.15 million74.71 millionOptionableCLBS, GNLX, NAUT, and KYTX HeadlinesRecent News About These CompaniesNautilus Biotechnology And 2 Other Penny Stocks With Promising PotentialMay 15, 2025 | uk.finance.yahoo.comNautilus Biotechnology (NASDAQ:NAUT) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPSMay 1, 2025 | marketbeat.comEarnings call transcript: Nautilus Biotechnology Q1 2025 surprises with EPS beatMay 1, 2025 | uk.investing.comNautilus Biotechnology Inc (NAUT) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions ...April 30, 2025 | finance.yahoo.comWhy Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 7.04%April 30, 2025 | aaii.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call TranscriptApril 30, 2025 | msn.comQ1 2025 Nautilus Biotechnology Inc Earnings CallApril 30, 2025 | uk.finance.yahoo.comNautilus Biotechnology targets late 2026 platform launch amid proteoform assay advancementsApril 29, 2025 | msn.comNautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.comNautilus Biotechnology Reports First Quarter 2025 Financial ResultsApril 29, 2025 | manilatimes.netNautilus Biotechnology (NAUT) Projected to Post Earnings on TuesdayApril 24, 2025 | marketbeat.comNautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025April 18, 2025 | seekingalpha.comWhy Nautilus Biotechnology, Inc.’s (NAUT) Stock Is Down 10.19%April 9, 2025 | aaii.comWe're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn RateApril 1, 2025 | finance.yahoo.comInsider Buying: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Purchases 53,300 Shares of StockMarch 22, 2025 | insidertrades.comGlobal Research Antibodies Market Poised for Remarkable Growth, Projected to Reach USD 9.6 Billion by 2032 | FMIMarch 4, 2025 | fmiblog.comNautilus Biotechnology price target lowered to $2.50 from $4 at GuggenheimFebruary 28, 2025 | markets.businessinsider.comNautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comNautilus Biotechnology Inc (NAUT) Q4 2024 Earnings Call Highlights: Progress in Proteome ...February 28, 2025 | finance.yahoo.comNautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026February 27, 2025 | msn.comNautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsFebruary 27, 2025 | taiwannews.com.twNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLBS, GNLX, NAUT, and KYTX Company DescriptionsCaladrius Biosciences NASDAQ:CLBSCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Genelux NASDAQ:GNLX$2.58 +0.09 (+3.61%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.60 +0.02 (+0.58%) As of 05/23/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Kyverna Therapeutics NASDAQ:KYTX$2.27 -0.20 (-8.10%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.26 -0.01 (-0.44%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Nautilus Biotechnology NASDAQ:NAUT$0.73 -0.05 (-6.62%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.08%) As of 05/23/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
